Accessible Search Form           Advanced Search

9. Research Grants


NHLBI Research Grants by Funding Mechanism: Fiscal Year 2006

  Number of Grants Total Cost
(Dollars in
Thousands)
Percent of
Total NHLBI
Research
Grant Dollars
Research Project Grants (RPGs)      
Research Project Grants (Excluding Small Business RPGs)      
Regular Research Grants (R01)
3,281 $1,322,778 58.12%
Small Research Grants (R03)
1 33 0.00
Program Project Grants (P01)
179 357,269 15.70
Cooperative Agreements (U01)
231 200,727 8.82
Area Grants (R15)
12 2,531 0.11
Explorative Developmental Grant (R21)
112 21,177 0.93
Method To Extend Research in Time (R37)
77 31,128 1.37
NIH Director's Pioneer Award (DP1)
0 312 0.01
Exploratory/Developmental Grants Phase II (R33)
7 2,634 0.12
Subtotal, Research Project Grants (Excluding Small Business RPGs)
3,900 1,938,589 85.17
Small Business Research Project Grants      
Small Business Technology Transfer (STTR Phase I) (R41)
21 3,059 0.13
Small Business Technology Transfer (STTR Phase II) (R42)
12 4,837 0.21
Small Business Innovation Research (SBIR Phase I) (R43)
54 9,237 0.41
Small Business Innovation Research (SBIR Phase II) (R44)
94 55,327 2.43
Subtotal, Small Business Research Project Grants
181 72,460 3.18
Subtotal, Research Project Grants
4,081 2,011,049 88.36
Research Center Grants      
Specialized Centers and Centers of Excellence (P50)
41 104,375 4.59
Sickle Cell Centers (U54)
11 23,928 1.05
Center for AIDS Research (P30)
0 2,961 0.13
Specialized Centers (Cooperative Agreements) (U54)
5 9,057 0.40
National Swine Research and Resource Center (U42)
1 765 0.03
Subtotal, Research Center Grants
58 141,086 6.20
Research Career Programs      
Mentored Research Development Award for Minority Faculty (K01)
40 5,453 0.24
Minority Institution Faculty Mentored Research Scientist Award (K01)
4 567 0.02
Mentored Scientist Development Award in Research Ethics (K01)
3 358 0.02
Independent Scientist Award (K02)
24 2,421 0.11
Research Career Award (K06)
1 34 0.00
Cultural Competence and Health Disparities Academic Award (K07)
18 2,109 0.09
Clinical Investigator Scientist Award (K08)
226 28,973 1.27
Vascular Medicine Research Career Development Program (K12)
2 772 0.03
Clinical Hematology Research Career Development Program (K12)
6 2,360 0.10
Career Enhancement Award for Stem Cell Research (K18)
2 213 0.01
Career Transition Award (K22)
1 178 0.01
Mentored Patient-Oriented Research Career Development Award (K23)
122 16,720 0.73
Midcareer Investigator Award in Patient-Oriented Research (K24)
33 4,315 0.19
Mentored Quantitative Research Career Development Award (K25)
16 2,184 0.10
Clinical Research Curriculum Award (K30)
14 3,708 0.16
Subtotal, Research Career Programs
512 70,365 3.10
Other Research Grants      
Cooperative Clinical Research (U10, R10)
47 33,684 1.48
Minority Biomedical Research Support (S06, S14, R25)
0 2,032 0.09
Other (R09, R13, R18, R24, R25, T15, U09, U24, UH1)
83 17,721 0.78
Subtotal, Other Research Grants
130 53,437 2.35
Total, NHLBI Research Grants 4,781 $2,275,937 100%

NHLBI Total Research Grants by Category

Grants by Category
Text-only with data points

NHLBI Research Project Grant,* Research Centers Grant, and Other Research Grant Obligations: Fiscal Years 1996–2005

NHLBI Research Project Grant,* Research Centers Grant, and Other Research Grant Obligations
Text-only with data points are represented in the table below.

NHLBI Research Project Grant,* Research Centers Grant, and Other Research Grant Obligations: Fiscal Years 1996–2006

  Fiscal Year
  1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Research Project Grants* $ 862,027 $ 935,322 $1,009,152 $1,142,473 $1,356,034 $1,580,751 $1,779,573 $1,920,201 $2,003,769 $2,042,050 $2,011,049
Research Centers Grants 106,688 108,665 114,397 119,889 123,803 127,232 128,161 138,941 140,600 151,495 141,086
Other Research Grants† 56,692 56,993 66,234 84,219 90,666 88,958 98,460 113,172 112,785 116,713 123,802
Total $1,025,407‡ $1,100,980 $1,189,783 $1,346,581 $1,570,503 $1,796,941 $2,006,194 $2,172,314 $2,257,154 $2,310,258 $2,275,937

* Includes R01, U01, P01, R03, R15, R29, R37, R41, R42, R43, and R44; R55 in 1996; R21 beginning in 1997; and R33 beginning in 2001.
† Includes Research Career Programs; excludes General Research Support Grants.
‡ Includes Program Evaluation and IMPAC II Assessment of $4,435,000.

NHLBI Competing Research Project Grant Applications*: Fiscal Years 1996–2006

Total Cost Dollars Reviewed and Awarded

NHLBI Competing Research Project Grant Applications*:  Fiscal Years 1996-2006
Text-only with data points are represented in the table below.

NHLBI Competing Research Project Grant Applications*: Fiscal Years 1996–2006

Total Cost Dollars Reviewed and Awarded

  Fiscal Year
  1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Applications Reviewed $699.2 $802.1 $687.1 $867.1 $809.8 $851.7 $1,221.7 $1,262.5 $1,277.6 $1,381.0 $1,577.7
Awarded 182.1 240.1 252.4 330.4 418.4 424.3 437.4 463.7 477.3 447.8 411.6

* Includes R01, U01, P01, R03, R15, R29, R37, R41, R42, R43, and R44; R55 in 1996; R21 beginning in 1997; and R33 beginning in 2001.

NHLBI Competing Research Project Grant Applications*: Fiscal Years 1996–2006

Number Reviewed and Awarded

NHLBI Competing Research Project Grant Applications*:  Fiscal Years 1996-2006
Text-only with data points are represented in the table below.

Number Reviewed and Awarded and Percent Funded

  Fiscal Year
  1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Applications Reviewed 2,605 2,771 2,657 2,704 2,893 2,895 3,064 3,098 3,548 3,865 4,412
RPGs Awarded 652 821 837 959 1,003 1,033 1,018 1,064 1,034 909 871
Success Rate (percent) 25.0 29.6 31.5 35.5 34.7 35.7 33.2 34.3 29.1 23.5 19.7

* Includes R01, U01, P01, R03, R15, R29, R37, R41, R42, R43, and R44; R55 in 1996; R21 beginning in 1997; and R33 beginning in 2001.

Percent of Reviewed Applications Funded (Success Rate)

Percent of Reviewed Applications Funded (Success Rate)
Text-only with data points

Back to Top

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations: Fiscal Years 1996–2006

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations:  Fiscal Years 1996-2006
Text-only with data points are represented in the table below.

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations: Fiscal Years 1996–2006

  Dollars (Millions)
  Fiscal Year
  1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Investigator-Initiated* $ 804.1 $ 867.9 $ 966.6 $1,069.9 $1,241.6 $1,446.2 $1,584.9 $1,681.9 $1,773.4 $1,822.9 $1,802.1
Institute-Initiated† 216.8 233.0 223.2 276.7 328.9 350.7 421.3 490.4 483.8 487.3 473.8
Total $1,020.9‡ $1,100.9 $1,189.8 $1,346.6 $1,570.5 $1,796.9 $2,006.2 $2,172.3 $2,257.2 $2,310.2 $2,275.9

* Includes R01, U01, P01, R03, R15, R29, R37, R41, R42, R43, and R44; R55 in 1996; R21 beginning in 1997; and R33 beginning in 2001.
† Includes Centers Grants and Cooperative Agreement RFAs.
‡ Excludes Program Evaluation Assessment of $4,435,000.

NHLBI Research Project Grants*: Amount Funded by Type of Award, Fiscal Years 1996–2006

  Dollars (Millions)
  Fiscal Year
  1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Competing                      
New Competing
$ 90.5 $135.8 $147.5 $ 202.0 $ 266.4 $ 280.0 $ 291.2 $ 285.5 $ 290.5 $ 270.0 $ 242.9
Renewal Competing
90.4 104 103.9 127.2 152 143.9 143.9 177.2 185.5 176.1 168.3
Competing Supplements
1.2 0.3 1 1.2 0.9 0.4 2.3 1 1.3 1.7 0.4
Subtotal, Competing 182.1 240.1 252.4 330.4 419.3 424.3 437.4 463.7 477.3 447.8 411.6
Noncompeting                      
Subtotal, Noncompeting 649.9 662.4 721.3 770.6 889.3 1,101.5 2,218.3 1,390.3 1,454.9 1,520.0 1,527.0
Total, Competing and Noncompeting $832.0 $902.5 $973.7 $1,101.0 $1,308.6 $1,525.8 $1,718.7 $1,854.0 $1,932.2 $1,967.8 $1,938.6
* Includes R01, U01, P01, R03, R15, R29, R37, R41, R42, R43, and R44; R55 in 1996; R21 beginning in 1997; and R33 beginning in 2001.

Facility and Administrative (F&A)* Costs of NHLBI Research Project Grants†: Fiscal Years 1996–2006

  Dollars
(Thousands)
Fiscal Year Direct Cost F&A Cost Total Cost F&A Cost as a Percent of Direct Cost
1996 $ 564,219 $267,785 $ 832,004 47.5%
1997 611,576 290,915 902,491 47.6
1998 660,009 313,765 973,774 47.5
1999 764,198 336,756‡ 1,100,954 44.1
2000 891,244 417,312 1,308,556 46.8
2001 1,045,144 480,673 1,525,817 46.0
2002 1,182,408 536,324 1,718,732 45.4
2003 1,276,819 577,131 1,853,950 45.2
2004 1,329,106 603,133 1,932,239 45.4
2005 1,355,803 612,007 1,967,810 45.1
2006 1,334,406 604,183 1,938,589 45.3

* Previously called Indirect Cost.
† Includes R01, U01, P01, R03, R15, R29, R37, R41, R42, R43, and R44; R55 in 1996; R21 beginning in 1997; and R33 beginning in 2001.
‡ Excludes Program Evaluation Assessment of $1,216,000.

NHLBI Research Project Grants*: Average Costs, Fiscal Years 1996–2006

NHLBI Research Project Grants*:  Average Costs, Fiscal Years 1996-2006
Text-only with data points are represented in the table below.

NHLBI Research Project Grants*: Average Costs, Fiscal Years 1996–2006

  Dollars (Thousands)
  Fiscal Year
  1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Noncompeting
$317.5 $323.0 $322.6 $323.4 $346.6 $390.7 $418.8 $444.4 $458.7 $490.6 $503.9
Competing
279.3 292.5 301.6 344.5 418 410.8 409.1 406.7 419.7 459.9 458.1
Total $308.3 $314.2 $316.9 $329.4 $366.6 $396.1 $416.2 $433.8 $447.9 $484.8 $492.8

* Includes R01, U01, P01, R03, R15, R29, R37, R41, R42, R43, and R44; R55 in 1996; R21 beginning in 1997; and R33 beginning in 2001.

NHLBI Cooperative Agreements (U01, U10) Programs

Cooperative Agreements were instituted to support discrete, circumscribed projects in areas of an investigator's specific interest and competency with substantial programmatic participation by the NHLBI during performance of the activity.

  Total Obligations Prior to FY 2006 Total FY 2006 Obligations Total Obligations to Date
Heart and Vascular Diseases      
AIM HIGH: Niacin Plus Statin To Prevent Vascular Events
$ 663,376 $ 6,323,911 $ 6,987,287
Atherosclerosis, Plaque, and CVD in Communities
9,930,706 3,328,404 13,259,110
Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D)
43,858,208 8,591,820 52,450,028
Cardiovascular Heart Study (CHS) Events Follow-Up Study
1,007,645 1,055,034 2,062,679
Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)
9,953,424 4,884,074 14,837,498
Claudication Exercise vs. Edoluminal Revascularization
1,368,413 1,478,581 2,846,994
Clinical Research Consortium To Improve Resuscitation Outcomes
16,224,715 9,183,943 25,408,658
Dynamic Evaluation of Percutaneous Coronary Intervention
5,455,365 725,054 6,180,419
Family Blood Pressure Program
88,494,060 4,732,732 93,226,792
Genetics of Coronary Artery Disease in Alaskan Natives (GOCADAN)
9,792,055 2,046,285 11,838,340
Girls Health Enrichment Multisite Studies (GEMS)
17,468,009 1,950,186 19,418,195
Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)
29,527,693 4,590,429 34,118,122
Heart Failure Clinical Research Network
5,642,461 5,642,461
Home Automatic External Defibrillator Trial (HAT)
15,064,384 2,114,588 17,178,972
IMMEDIATE Trial: Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care
14,684,147 10,966,492 25,650,639
Interaction of Genes and Environment in Shaping Risk Factors for Heart, Lung, and Blood Diseases and Sleep Disorders
46,072,888 640,556 46,713,444
NHLBI Clinical Proteomics Program
5,103,660 4,920,669 10,024,329
Partnership Programs for Reducing Cardiovascular Health Disparities
13,670,752 7,258,374 20,929,126
Pediatric Heart Network
6,988,223 6,988,223
Pharmacogenetics Research Network
39,541,200 8,983,384 48,524,584
Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST)
4,916,790 1,863,033 6,779,823
Primordial Prevention of Overweight in American Indian Children
354,427 2,083,097 2,437,524
Programs of Excellence in Nanotechnology
6,322,873 11,230,687 17,553,560
Programs of Genomic Applications (PGAs) for Heart, Lung, and Blood Diseases
180,640,497 14,467,114 195,107,611
Stop Atherosclerosis in Native Diabetics Study (SANDS)
9,004,979 2,074,057 11,079,036
Strong Heart Study
51,738,304 6,235,839 57,974,143
Surgical Treatment for Ischemic Heart Failure (STICH)
19,946,837 5,583,045 25,529,882
Trial of Activity for Adolescent Girls (TAAG)
33,305,766 905,336 34,211,102
Weight Loss in Obese Adults With Cardiovascular Risk Factors: Clinical Interventions
2,567,146 2,567,146
Weight Loss Maintenance (WLM)
11,153,382 4,014,660 15,168,042
Subtotal, Heart and Vascular Diseases 685,264,555 147,429,214 825,705,546
Lung Diseases      
Asthma Clinical Research Network (ACRN), Phase II
25,272,584 7,838,310 33,110,894
Centers for Reducing Asthma Disparities
22,404,795 4,946,024 27,350,819
Childhood Asthma Management Program-Continuation Study (CAMP-CS)/Phase 2
6,155,523 2,750,045 8,905,568
Childhood Asthma Research and Education (CARE) Network
37,102,539 5,734,754 42,837,293
Clinical Trial of Acid Reflux Therapy in Asthma
2,310,686 772,866 3,083,552
Collaborative Programs in Bronchopulmonary Dysplasia
31,656,005 5,075,067 36,731,072
COPD Clinical Research Network
22,129,545 7,664,383 29,793,928
Early Antipseudomonal Therapy in Cystic Fibrosis
2,111,618 1,033,655 3,145,273
Idiopathic Pulmonary Fibrosis Clinical Research Network
3,486,226 7,349,196 10,835,422
Pharmacogenetics of Asthma Treatment
14,209,020 3,285,718 17,494,738
Prospective Investigation of Pulmonary Embolism Diagnosis III (PIOPED III)
2,301,770 4,341,911 6,643,681
Study of Acid Reflux Therapy for Children With Asthma
774,454 774,454
Subtotal, Lung Diseases 169,140,311 51,566,383 219,932,240
Blood Diseases and Resources      
Blood and Marrow Transplant Clinical Research Network
29,641,551 6,845,170 36,486,721
Center for Human Cell Therapy
5,179,743 2,101,631 7,281,374
Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS)
6,357,932 2,446,287 8,804,219
Sickle Cell Disease Clinical Research Network
3,761,385 3,761,385
Stroke With Transfusions Changing to Hydroxyurea (SWITCH)
3,345,345 3,931,995 7,277,340
Thalassemia (Cooley's Anemia) Clinical Research Network
14,104,677 2,682,493 16,787,170
Transfusion Medicine/Hemostasis Clinical Research Network
24,607,616 6,520,638 31,128,254
Subtotal, Blood Diseases and Resources 83,236,864 28,289,599 111,526,463
National Center on Sleep Disorders Research      
Apnea Positive Pressure Long-Term Efficacy Study (APPLES)
12,542,181 12,542,181
Randomized Controlled Study of Adenotonsillectomy for Childhood Sleep Apnea
2,267,140 2,267,140
Sleep Heart Health Study
19,603,693 907,548 20,511,241
Subtotal, National Center on Sleep Disorders Research 32,145,874 3,174,688 35,320,562
Total, NHLBI Cooperative Agreements $969,787,604 $230,459,884 $1,192,484,811

Heart and Vascular Diseases Program

AIM HIGH: Niacin Plus Statin To Prevent Vascular Events, Initiated in Fiscal Year 2005

The purpose of this multicenter clinical trial is to determine whether extended-release niacin plus simvastatin is superior to simvastatin alone for preventing or delaying a major CVD event in patients with atherogenic dyslipidemia. Niacin is used to raise HDL ("good") cholesterol and simvastatin is used to lower LDL ("bad") cholesterol. Twenty-seven percent of the population will be black.

Obligations

Funding History:
   Fiscal Year 2006—$6,323,911
    Fiscal Year 2005—$663,376
Total Funding to Date—$6,987,287

Current Active Organizations and Grant Numbers

  1. University of Washington
    Seattle, Washington —HL-081616
  2. AXIO Research, LLC
    Seattle, Washington —HL-081649

Atherosclerosis, Plaque, and CVD in Communities, Initiated in Fiscal Year 2004

The purpose of this study is to identify correlates of atherosclerotic plaque characteristics and early changes in the vascular wall in a subset of the biethnic Atherosclerosis Risk in Communities (ARIC) cohort. Investigators will use stored DNA samples to test genomic correlates of plaque characteristics and their ability to predict CHD and stroke.

Obligations

Funding History:
    Fiscal Year 2006—$3,328,404
    Fiscal Year 2004–2005—$9,930,706
Total Funding to Date—$13,259,110

Current Active Organization and Grant Number

  1. University of Texas Health Science Center
    Houston, Texas —HL-075572

Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D), Initiated in Fiscal Year 2000

The purpose of this trial is to compare alternative treatment strategies for managing Type 2 diabetic patients with angiographically proven coronary artery disease and stable angina or ischemia. Revascularization combined with aggressive medical anti-ischemia treatment will be compared to aggressive medical anti-ischemia treatment alone; simultaneously, researchers will determine whether insulin-sensitizing drugs like metformin and the glitazones for controlling blood sugar level offer any survival advantage over drugs that increase insulin level. Twenty percent of the patients are from minority populations.

Obligations

Funding History:
   Fiscal Year 2006—$8,591,820
   Fiscal Years 2000–2005—$43,854,208
Total Funding to Date—$52,450,028

Current Active Organizations and Grant Numbers

  1. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-061744
  2. St. Louis University
    St. Louis, Missouri —HL-061746
  3. Stanford University
    Stanford, California —HL-061748
  4. University of Vermont
    Burlington, Vermont —HL-063804

Cardiovascular Heart Study (CHS) Events Follow-Up Study, Initiated in Fiscal Year 2005

The purpose of this project is to continue follow-up of the CHS cohort for cardiovascular events in order to enhance power among subgroups to study associations of CVD risk factors and incidence and prognosis following CVD events in older adults. The additional events will permit greater opportunity to address the study aims by CHS investigators and other researchers interested in making use of the study's extensive database and specimens. Seventeen percent of the participants are from minority populations.

Obligations

Funding History:
   Fiscal Year 2006—$1,055,034
   Fiscal Year 2005—$1,007,645
Total Funding to Date—$2,062,679

Current Active Organization and Grant Number

  1. University of Washington
    Seattle, Washington —HL-080295

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), Initiated in Fiscal Year 2004

The purpose of this trial is to determine whether revascularization of a stenotic renal artery plus medical therapy is associated with improved clinical outcomes compared with medical therapy alone. Thirty percent of the participants will be black.

Obligations

Funding History:
   Fiscal Year 2006—$4,884,074
   Fiscal Year 2004–2005—$9,953,424
Total Funding to Date—$14,837,498

Current Active Organizations and Grant Numbers

  1. Medical University of Ohio
    Toledo, Ohio —HL-071556
  2. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HL-072734
  3. University of Virginia
    Charlottesville, Virginia —HL-072735
  4. Beth Israel Deaconess Medical Center
    Boston, Massachusetts —HL-072736
  5. Brigham and Women's Hospital
    Boston, Massachusetts —HL-072737

Claudication Exercise vs. Edoluminal Revascularization, Initiated in Fiscal Year 2005

The purpose of this study is to test the hypothesis that a strategy of aortoiliac stenting and pharmacotherapy improves maximum walking duration better than a strategy of supervised rehabilitation, exercise, and pharmacotherapy for those with aortoiliac artery obstruction at 6 months. Other objectives are to compare the two treatment groups with a third group, usual care and pharmacotherapy, at 6 months, and to compare maximum walking duration change scores at 18 months, changes in free living daily activity levels, and patient-perceived quality of life among all three groups.

Obligations

Funding History:
   Fiscal Year 2006—$1,478,581
   Fiscal Year 2005—$1,368,413
Total Funding to Date—$2,846,994

Current Active Organizations and Grant Numbers

  1. Rhode Island Hospital
    Providence, Rhode Island —HL-077221
  2. Brigham and Women's Hospital
    Boston, Massachusetts —HL-081656

Clinical Research Consortium To Improve Resuscitation Outcomes, Initiated in Fiscal Year 2004

See Chapter 11. Clinical Trials.

Dynamic Evaluation of Percutaneous Coronary Intervention, Initiated in Fiscal Year 1997

This program, which complements prior NHLBI percutaneous transluminal coronary angioplasty (PTCA) registries and the New Approaches to Coronary Intervention Registry, is evaluating patterns of device usage, as well as immediate and follow-up outcomes in patients undergoing percutaneous transluminal coronary revascularization. Results will provide guidance to the cardiology community in selecting appropriate therapies and in designing clinical trials to evaluate competing devices.

Obligations

Funding History:
   Fiscal Year 2006—$725,054
   Fiscal Years 1997–2005—$5,455,365
Total Funding to Date—$6,180,419

Current Active Organization and Grant Number

  1. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-033292

Family Blood Pressure Program, Initiated in Fiscal Year 1995

The objectives of this program are to identify major genes associated with high blood pressure and to investigate the interactions between genetic and environmental determinants of hypertension in defined populations, many of which consist of specific minority groups. The study consists of collaborative networks that share technology, data, skills, biological materials, and population resources.

Obligations

Funding History:
   Fiscal Year 2006—$4,732,732
   Fiscal Years 1995–2005—$88,494,060
Total Funding to Date—$93,226,792

Current Active Organizations and Grant Numbers

  1. University of Utah
    Salt Lake City, Utah —HL-054471
  2. Washington University
    St. Louis, Missouri —HL-054473
  3. University of Texas
    Health Science Center
    Houston, Texas —HL-054481
  4. Pacific Health Research Institute
    Honolulu, Hawaii —HL-054498
  5. University of Michigan at Ann Arbor
    Ann Arbor, Michigan —HL-054512

Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN), Initiated in Fiscal Year 2000

The purpose of this study is to document CVD and CVD risk factors in approximately 40 extended families (1,214 members from villages in Northern Alaska). Scientists seek to identify and characterize genes that contribute to CVD in this unique and understudied population.

Obligations

Funding History:
   Fiscal Year 2006—$2,046,285
   Fiscal Years 2000–2005—$9,792,055
Total Funding to Date—$11,838,340

Current Active Organizations and Grant Numbers

  1. MedStar Research Institute
    Washington, DC —HL-064244
  2. Norton Sound Health Corporation
    Nome, Alaska —HL-082458
  3. Southwest Foundation for
    Biomedical Research
    San Antonio, Texas —HL-082490

Girls Health Enrichment Multisite Studies (GEMS), Initiated in Fiscal Year 1999

The objective of this project is to develop and test interventions to prevent obesity by decreasing weight gain during the high-risk transitional period from pre-puberty to puberty in black girls who are at risk for developing obesity. Phase I (developmental and pilot studies) was completed in FY 2002. Two sites began Phase II trials in FY 2003.

Obligations

Funding History:
   Fiscal Year 2006—$1,950,186
   Fiscal Years 1999–2005—$17,468,009
Total Funding to Date—$19,418,195

Current Active Organizations and Grant Numbers

  1. University of Memphis
    Memphis, Tennessee —HL-062662
  2. Stanford University
    Stanford, Califorinia —HL-062663

Heart Failure: A Controlled Trial Investigating Outcomes of Exercise (HF-ACTION), Initiated in Fiscal Year 2002

The purpose of this trial is to determine the long-term safety and effectiveness of exercise training for patients with heart failure. Patients receiving the exercise regimen also will receive standard care and will be compared with patients receiving standard care alone.

Obligations

Funding History:
   Fiscal Year 2006—$4,590,429
   Fiscal Years 2002–2005—$29,527,693
Total Funding to Date—$34,118,122

Current Active Organizations and Grant Numbers

  1. Duke University
    Durham, North Carolina —HL-063747
  2. Case Western Reserve University
    Henry Ford Health System
    Detroit, Michigan —HL-064250
  3. Oregon Health & Science University
    Portland, Oregon —HL-064257
  4. Washington University
    St. Louis, Missouri —HL-064264
  5. University of Colorado
    Health Sciences Center
    Denver, Colorado —HL-064265
  6. Duke University
    Durham, North Carolina —HL-066461
  7. Emory University
    Atlanta, Georgia —HL-066482
  8. Wake Forest University
    Winston-Salem, North Carolina —HL-066491
  9. Ohio State University
    Columbus, Ohio —HL-066494
  10. University of Alabama at Birmingham
    Birmingham, Alabama —HL-066497
  11. Case Western Reserve University
    Cleveland, Ohio —HL-066501
  12. Boston Medical Center
    Boston, Massachusetts —HL-068973
  13. University of California, Los Angeles
    Los Angeles, California —HL-068980

Heart Failure Clinical Research Network, Initiated in Fiscal Year 2006

The purpose of this network is to accelerate research in the diagnosis and management of heart failure in order to improve outcomes through optimal application of existing therapies and evaluation of novel therapies.

Obligations

Funding History:
   Fiscal Year 2006—$5,642,461
Total Funding to Date—$5,642,461

Current Active Organizations and Grant Numbers

  1. Minneapolis Medical Research Foundation
    Minneapolis, Minnesota —HL-084861
  2. Duke University
    Durham, North Carolina —HL-084875
  3. Brigham and Women's Hospital
    Boston, Massachusetts —HL-084877
  4. University of Utah
    Salt Lake City, Utah —HL-084889
  5. Baylor College of Medicine
    Houston, Texas —HL-084890
  6. University of Vermont
    Burlington, Vermont —HL-084899
  7. Duke University
    Durham, North Carolina —HL-084904
  8. Mayo Clinic College of Medicine
    Rochester, Minnesota —HL-084907
  9. Montreal Heart Institute
    Montreal, Quebec —HL-084931

Home Automatic External Defibrillator Trial (HAT), Initiated in Fiscal Year 2002

The purpose of this trial is to compare standard response (call 9-1-1 and give cardiopulmonary resuscitation) to sudden cardiac arrest to standard response augmented with automatic external defibrillator use provided by a spouse or other family member in 7,000 survivors of an anterior wall MI. The primary end point is mortality.

Obligations

Funding History:
   Fiscal Year 2006—$2,114,588
   Fiscal Years 2002–2005—$15,064,384
Total Funding to Date—$17,178,972

Current Active Organization and Grant Number

  1. Seattle Institute for Cardiac Research
    Seattle, Washington —HL-067972

IMMEDIATE Trial: Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care, Initiated in Fiscal Year 2004

The purpose of this program is to study the effects of early administration of glucose, insulin, and potassium (GIK) in reducing mortality in patients from acute coronary syndrome (ACS). Patients experiencing an ACS (including AMI and unstable angina pectoris) will be treated with GIK as soon as possible in prehospital emergency medical service settings or immediately upon arrival for those presenting to emergency departments.

Obligations

Funding History:
   Fiscal Year 2006—$10,966,492
   Fiscal Year 2004–2005—$14,684,147
Total Funding to Date—$25,650,639

Current Active Organizations and Grant Numbers

  1. New England Medical Center Hospitals
    Boston, Massachusetts —HL-077821
  2. State University of New York
    Stony Brook, New York —HL-077822
  3. New England Medical Center Hospitals
    Boston, Massachusetts —HL-077823
  4. New England Medical Center Hospitals
    Boston, Massachusetts —HL-077826

Interaction of Genes and Environment in Shaping Risk Factors for Heart, Lung, and Blood Diseases and Sleep Disorders, Initiated in Fiscal Year 2002

The purpose of this study is to identify novel genes that interact with specific environmental exposures to modify risk factors for heart, lung, and blood diseases and sleep disorders. The genetic aspects of response to environmental change and related biological mechanisms will be studied using short-term, focused interventions in families. Subgroups will be identified based on genotypes that are most likely to benefit from targeted environmental changes designed to reduce the development or progression of heart, lung, and blood diseases or sleep disorders.

Obligations

Funding History:
   Fiscal Year 2006—$640,556
   Fiscal Years 2002–2005—$46,072,888
Total Funding to Date—$46,713,444

Current Active Organizations and Grant Numbers

  1. Tulane University
    New Orleans, Louisiana —HL-072507
  2. LSU Pennington Biomedical
    Research Center
    Baton Rouge, Louisiana —HL-072510
  3. University of Maryland
    Baltimore Professional School
    Baltimore, Maryland —HL-072515
  4. Johns Hopkins University
    Baltimore, Maryland —HL-072518
  5. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HL-072524

NHLBI Clinical Proteomics Program, Initiated in Fiscal Year 2005

The purpose of this program is to promote systematic, comprehensive, large-scale validation of existing and new candidate protein markers that are appropriate for routine use in the diagnosis and management of heart, lung, and blood diseases and sleep disorders. The Program will facilitate validation of protein panels that may be used to predict disease susceptibility or to assist in differential diagnosis, disease staging, selection of individualized therapies, or monitoring of treatment responses. It will also establish a high-quality education and skills development program to ensure that scientists develop the expertise needed to address the complex, multifaceted challenges in clinical proteomics.

Obligations

Funding History:
   Fiscal Year 2006—$4,920,669
   Fiscal Year 2005—$5,103,660
Total Funding to Date—$10,024,329

Current Active Organizations and Grant Numbers

  1. Mayo Clinic College of Medicine
    Rochester, Minnesota —HL-081331
  2. Vanderbilt University
    Nashville, Tennessee —HL-081332
  3. University of Colorado
    Denver, Colorado —HL-081335
  4. Masschusetts General Hospital
    Boston, Massachusetts —HL-081341

Partnership Programs To Reduce Cardiovascular Health Disparities, Initiated in Fiscal Year 2004

The objectives of this study are to improve the provider and patient approaches to treatment of hypertension and diabetes, modify physician-related barriers to minority enrollment in clinical trials, improve patient adherence to treatment plans, and build sustainable research programs at minority-serving institutions.

Obligations

Funding History:
   Fiscal Year 2006—$7,258,374
   Fiscal Year 2004–2005—$13,670,752
Total Funding to Date—$20,929,126

Current Active Organizations and Grant Numbers

  1. Bon Secours Hospital Baltimore, Inc.
    Baltimore, Maryland —HL-079150
  2. University of Maryland
    Baltimore Professional School
    Baltimore, Maryland —HL-079151
  3. Queen's Medical Center
    Honolulu, Hawaii —HL-079152
  4. Cooper Green Hospital
    Birmingham, Alabama —HL-079153
  5. Emory University
    Atlanta, Georgia —HL-079156
  6. Denver Health and Hospital Authority
    Denver, Colorado —HL-079160
  7. University of Hawaii at Manoa
    Honolulu, Hawaii —HL-079163
  8. University of Alabama at Birmingham
    Birmingham, Alabama —HL-079171
  9. University of Colorado
    Health Sciences Center
    Denver, Colorado —HL-079208
  10. Morehouse School of Medicine
    Atlanta, Georgia —HL-079214
  11. Jackson Hinds Comprehensive
    Health Center
    Jackson, Mississippi —HL-079378
  12. University of Mississippi
    Medical Center
    Jackson, Mississippi—HL-079458

Pediatric Heart Network, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Pharmacogenetics Research Network, Initiated in Fiscal Year 2001

The purpose of this study is to establish a network to systematically evaluate candidate genes that may influence pharmacologic response to drug treatments for arrhythmia, heart failure, hypertension, and lipid disorders. Investigators seek to identify gene polymorphisms capable of predicting drug toxicity and efficacy. One of the projects has 50 percent minority participation.

Obligations

Funding History:
   Fiscal Year 2006—$8,983,384
   Fiscal Years 2001–2005—$39,541,200
Total Funding to Date—$48,524,584

Current Active Organizations and Grant Numbers

  1. Vanderbilt University
    Nashville, Tennessee —HL-065962
  2. Children's Hospital and Research Center
    Oakland, California —HL-069757
  3. Stanford University
    Stanford, California —GM-061374

Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST), Initiated in Fiscal Year 2003

The purpose of this study is to compare the effects of four diets low in saturated fat and differing in macronutrient composition on weight loss and its maintenance in 800 overweight or obese adults. The diet consists of moderate fat (40 percent energy) or low fat (20 percent energy) with two different protein levels (15 and 25 percent). Approximately 20 percent of the participants will be minority.

Obligations

Funding History:
   Fiscal Year 2006—$1,863,033
   Fiscal Years 2003–2005—$4,916,790
Total Funding to Date—$6,779,823

Current Active Organization and Grant Number

  1. Harvard School of Public Health
    Boston, Massachusetts —HL-073286

Primordial Prevention of Overweight in American Indian Children, Initiated in Fiscal Year 2005

The purpose of this study is to prevent early childhood overweight in American Indian children. A cohort of children born over an 18-month period will be randomized to either a control or intervention condition. The intervention comprises a community-wide intervention coupled with individualized family counseling to improve nutrition and physical activity in infants and toddlers. A central feature of the project is to develop and test culturally appropriate interventions that can be incorporated into clinical programs of the community health care systems or delivered through public health approaches in Native communities.

Obligations

Funding History:
   Fiscal Year 2006—$2,083,097
   Fiscal Year 2005—$354,427
Total Funding to Date—$2,437,524

Current Active Organizations and Grant Numbers

  1. Kaiser Foundation Research Institutes
    Oakland, California —HL-081624
  2. University of Washington
    Seattle, Washington —HL-087322
  3. University of Oklahoma
    Oklahoma City, Oklahoma —HL-087354
  4. University of Wisconsin
    Madison, Wisconsin —HL-087381
  5. Black Hills Center/American Indian Health
    Rapid City, South Dakota —HL-087422

Programs of Excellence in Nanotechnology, Initiated in Fiscal Year 2005

The purpose of this program is to establish multidisciplinary teams to develp nanotechnology and biomolecular engineering tools and methodologies to detect and analyze atherosclerotic plaque formation. The program presents an unique opportunity for research collaboration and skills training by bring bioengineering and nanotechnology solutions into medicine and vice versa.

Obligations

Funding History:
   Fiscal Year 2006—$11,230,687
   Fiscal Year 2005—$6,322,873
Total Funding to Date—$17,553,560

Current Active Organizations and Grant Numbers

  1. Emory University
    Atlanta, Georgia —HL-080711
  2. Burnham Institute for Medical Research
    La Jolla, California —HL-080718
  3. Washington University
    St. Louis, Missouri —HL-080729
  4. Massachusetts General Hospital
    Boston, Massachusetts —HL-080731

Programs of Genomic Applications (PGAs) for Heart, Lung, and Blood Diseases, Initiated in Fiscal Year 2000

The goal of this program is to develop information, tools, and resources to link genes to biological function. Specifically, researchers seek to identify human genes relevant to heart, lung, blood, and sleep functions. In addition, the PGAs will establish training programs for NHLBI-supported investigators in the use of genomic information and technologies.

Obligations

Funding History:
   Fiscal Year 2006—$14,467,114
   Fiscal Years 2000–2005—$180,640,497
Total Funding to Date—$195,107,611

Current Active Organizations and Grant Numbers

  1. Medical College of Wisconsin
    Milwaukee, Wisconsin —HL-066579
  2. University of California, San Francisco
    San Francisco, California —HL-066600
  3. Jackson Laboratory
    Bar Harbor, Maine —HL-066611
  4. University of California, Los Angeles
    Los Angeles, California —HL-066621
  5. University of Washington
    Seattle, Washington —HL-066642
  6. University of California
    Lawrence Berkeley Laboratory
    Berkeley, California —HL-066681
  7. University of Washington
    Seattle, Washington —HL-066682

Stop Atherosclerosis in Native Diabetics Study (SANDS), Initiated in Fiscal Year 2002

This study will address the high incidence of CVD in a population with a high prevalence of diabetes, but relatively low levels of LDL cholesterol and blood pressure. It will compare aggressive lowering of LDL cholesterol and blood pressure to the usual care standard.

Obligations

Funding History:
   Fiscal Year 2006—$2,074,057
   Fiscal Years 2002–2005—$9,004,979
Total Funding to Date—$11,079,036

Current Active Organization and Grant Number

  1. MedStar Research Institute
    Washington, DC —HL-067031

Strong Heart Study, Initiated in Fiscal Year 1988

The objectives of this study are to survey CVD morbidity and mortality rates among three geographically diverse groups of American Indians and to estimate their levels of CVD risk factors. Phases II and III of the cohort study extended surveillance of community mortality and assessed development of CVD and changes in CVD risk factors. In Phase III, investigators added a substudy of asthma and a pilot family study. Phase IV expanded the family study to 120 families comprising 3,600 members to investigate genetic and environmental contributors of CVD. Phase V will examine the family study cohort to assess genetic relationships to risk factor change over a 5‑year period.

Obligations

Funding History:
   Fiscal Year 2006—$6,235,839
   Fiscal Years 1988–2005—$51,738,304
Total Funding to Date—$57,974,143

Current Active Organizations and Grant Numbers

  1. MedStar Research Institute
    Washington, DC —HL-041642
  2. Missouri Breaks Research, Inc.
    Timberlake, South Dakota —HL-041652
  3. University of Oklahoma
    Health Sciences Center
    Oklahoma City, Oklahoma —HL-041654
  4. Southwest Foundation for
    Biomedical Research
    San Antonio, Texas —HL-065520
  5. Weill Medical College of
    Cornell University
    New York, New York —HL-065521

Surgical Treatment for Ischemic Heart Failure (STICH), Initiated in Fiscal Year 2002

The purpose of this clinical trial is to determine whether CABG plus intensive medical therapy improves long-term survival of patients with heart failure and left ventricular (LV) dysfunction who have coronary artery disease amenable to surgical revascularization, compared to medical therapy alone; and to determine whether CABG plus surgical ventricular restoration to a more normal LV size improves survival free of subsequent hospitalizations of patients with anterior LV dysfunction, compared to CABG alone.

Obligations:

Funding History:
   Fiscal Year 2006—$5,583,045
   Fiscal Years 2002–2005—$19,946,837
Total Funding to Date—$25,529,882

Current Active Organizations and Grant Numbers

  1. Thomas Jefferson University
    Philadelphia, Pennsylvania —HL-069009
  2. Mayo Clinic College of Medicine
    Rochester, Minnesota —HL-069010
  3. Duke University
    Durham, North Carolina —HL-069011
  4. Northwestern University
    Chicago, Illinois —HL-069012
  5. Duke University
    Durham, North Carolina —HL-069013
  6. Duke University
    Durham, North Carolina —HL-069015
  7. University of Southern California
    Los Angeles, California —HL-072683

Trial of Activity for Adolescent Girls (TAAG), Initiated in Fiscal Year 2000

See Chapter 11. Clinical Trials.

Weight Loss in Obese Adults With Cardiovascular Risk Factors: Clinical Interventions, Initiated in Fiscal Year 2006

The purpose of this study is to conduct clinical trials in primary care settings to test the effectiveness of weight loss interventions in obese patients who have additional cardiovascular risk factors. An important secondary focus of the effectiveness trials is to test strategies to improve patient adherence to evidence-based guidelines to reduce the other cardiovascular risk factors (e.g., elevated lipids, hypertension, or cigarette smoking) commonly present in obese individuals.

Obligations

Funding History:
   Fiscal Year 2006—$2,567,146
Total Funding to Date—$2,567,146

Current Active Organizations and Grant Numbers

  1. Brigham and Women's Hospital
    Boston, Massachusetts —HL-087071
  2. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-087072
  3. Johns Hopkins University
    Baltimore, Maryland —HL-087085

Weight Loss Maintenance (WLM), Initiated in Fiscal Year 2003

The purpose of this multicenter trial is to evaluate the effectiveness of two strategies to maintain weight loss for 2½ years in approximately 800 overweight or obese adults. Individuals who are taking medication for hypertension of dyslipidemia or who are diabetic enter a 6-month weight program. Those who lose at least 9 pounds are randomized into one of three groups: one that provides monthly personal contacts with a trained interventionist, primarily by telephone; one that provides frequent contacts through an interactive Web-based program; or usual care. Forty percent of the participants will be black.

Obligations

Funding History:
   Fiscal Year 2006—$4,014,660
   Fiscal Years 2003–2005—$11,153,382
Total Funding to Date—$15,168,042

Current Active Organizations and Grant Numbers

  1. Center for Health Research
    Portland, Oregon —HL-068676
  2. Duke Hypertensive Center
    Durham, North Carolina —HL-068734
  3. Center for Health Research
    Portland, Oregon —HL-068790
  4. Johns Hopkins University
    Baltimore, Maryland —HL-068920
  5. LSU Pennington Biomedical
    Research Center
    Baton Rouge, Louisiana —HL-068955

Lung Diseases Program

Asthma Clinical Research Network (ACRN) Phase II, Initiated in Fiscal Year 2003

See Chapter 11. Clinical Trials.

Centers for Reducing Asthma Disparities, Initiated in Fiscal Year 2002

The purpose of this study is to establish cooperative centers of research to reduce asthma disparities between whites and minorities and economically disadvantaged populations. The mission of the centers, comprising partnerships between minority-servicing medical institutions and research-intensive institutions, is to promote interdisciplinary investigation of factors that contribute to disparities in asthma, accelerate development and evaluation of strategies to promote effective asthma management among minority and economically disadvantaged populations, encourage training and career development for minority clinical research investigators, and improve the effectiveness of NHLBI-supported research-intensive institutions in developing and sustaining culturally appropriate research and demonstration activities on reducing disparities.

Obligations

Funding History:
   Fiscal Year 2006—$4,946,024
   Fiscal Years 2002–2005—$22,404,795
Total Funding to Date—$27,350,819

Current Active Organizations and Grant Numbers

  1. Meharry Medical College
    Nashville, Tennessee —HL-072431
  2. Howard University
    Washington, DC —HL-072433
  3. Rhode Island Hospital
    Providence, Rhode Island —HL-072438
  4. Johns Hopkins University
    Baltimore, Maryland —HL-072455
  5. Vanderbilt University
    Nashville, Tennessee —HL-072471
  6. Northwestern University
    Chicago, Illinois —HL-072478
  7. Hektoen Institute for Medical Research
    Chicago, Illinois —HL-072496
  8. University of Puerto Rico
    Medical Sciences
    San Juan, Puerto Rico —HL-072519

Childhood Asthma Management Program-Continuation Study (CAMP-CS)/Phase 2, Initiated in Fiscal Year 2003

The objectives of this observational study are to follow the original CAMP cohort for 4 more years into early adulthood to determine the effects of long-term (3.5 to 5.5 years) corticosteroid therapy, started at ages 5 to 12, on outcomes of pulmonary function, height, bone density, and clinical course of asthma; 31 percent of the participants are from minority groups.

Obligations

Funding History:
   Fiscal Year 2006—$2,750,045
   Fiscal Years 2003–2005—$6,155,523
Total Funding to Date—$8,905,568

Current Active Organizations and Grant Numbers

  1. Washington University
    St. Louis, Missouri —HL-075232
  2. Hospital for Sick Children
    Toronto, Ontario —HL-075407
  3. Johns Hopkins University
    Baltimore, Maryland —HL-075408
  4. Asthma, Inc.
    Seattle, Washington —HL-075409
  5. University of California, San Diego
    La Jolla, California —HL-075415
  6. National Jewish Medical
    and Research Center
    Denver, Colorado —HL-075416
  7. Johns Hopkins University
    Baltimore, Maryland —HL-075417
  8. Brigham and Women's Hospital
    Boston, Massachusetts —HL-075419
  9. University of New Mexico
    Albuquerque, New Mexico —HL-075420

Childhood Asthma Research and Education (CARE) Network, Initiated in Fiscal Year 1999

See Chapter 11. Clinical Trials.

Clinical Trial of Acid Reflux Therapy in Asthma, Initiated in Fiscal Year 2003

The purpose of this clinical trial is to test the hypothesis that treatment of gastroesophageal reflux with proton-pump inhibitors will reduce the frequency of exacerbations in patients with inadequately controlled asthma.

Obligations

Funding History:
   Fiscal Year 2006—$772,866
   Fiscal Year 2003–2005—$2,310,686
Total Funding to Date—$3,083,552

Current Active Organization and Grant Number

  1. Johns Hopkins University
    Baltimore, Maryland —HL-072968

Collaborative Program in Bronchopulmonary Dysplasia, Initiated in Fiscal Year 1999

The objectives of this program are to support a multi-institutional collaborative research effort by providing a well-defined model of prematurity and bronchopulmonary dysplasia to investigators, and to study mechanisms of lung pathobiology that underlie development of chronic lung disease of prematurity.

Obligations

Funding History:
   Fiscal Year 2006—$5,075,067
   Fiscal Years 1999–2005—$31,656,005
Total Funding to Date—$36,731,072

Current Active Organizations and Grant Numbers

  1. Southwest Foundation
    for Biomedical Research
    San Antonio, Texas —HL-052636
  2. Brigham and Women's Hospital
    Boston, Massachusetts —HL-052638
  3. University of California, San Francisco
    San Francisco, California —HL-056061
  4. National Jewish Medical
    and Research Center
    Denver, Colorado —HL-056263
  5. Barnes Jewish Hospital
    St. Louis, Missouri —HL-063387
  6. National Jewish Medical
    and Research Center
    Denver, Colorado —HL-063397
  7. University of Texas
    Southwestern Medical Center
    Dallas, Texas —HL-063399
  8. University of Rochester
    Rochester, New York —HL-063400
  9. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania —HL-075900

COPD Clinical Research Network, Initiated in Fiscal Year 2003

See Chapter 11. Clinical Trials.

Early Antipseudomonal Therapy in Cystic Fibrosis, Initiated in Fiscal Year 2004

The purpose of this study is to determine a safe, effective, and systematic approach for treating young children (ages 1 to 12 years) with cystic fibrosis who are found to be infected with Pseudomonas aemginosa (Pa). The goal is to intervene with antipseudomonal therapy at the first isolation of Pa to delay or prevent chronic infections that lead to irreversible lung destruction.

Obligations

Funding History:
   Fiscal Year 2006—$1,033,655
   Fiscal Year 2004–2005—$2,111,618
Total Funding to Date—$3,145,273

Current Active Organization and Grant Number

  1. Children's Hospital
    and Regional Medical Center
    Seattle, Washington —HL-080310

Idiopathic Pulmonary Fibrosis Clinical Research Network, Initiated in Fiscal Year 2005

See Chapter 11. Clinical Trials.

Pharmacogenetics of Asthma Treatment, Initiated in Fiscal Year 2000

The objective of this project is to bring together research experts in asthma, epidemiology, statistics, bioinformatics, physiology, clinical trials, genetics, and genomics to focus on the pharmacogenetics of asthma treatment.

Obligations

Funding History:
   Fiscal Year 2006—$3,285,718
   Fiscal Years 2000–2005—$14,209,020
Total Funding to Date—$17,494,738

Current Active Organization and Grant Number

  1. Brigham and Women's Hospital
    Boston, Massachusetts —HL-065899

Prospective Investigation of Pulmonary Embolism Diagnosis III (PIOPED III), Initiated in Fiscal Year 2005

The purpose of this study is to determine the diagnostic accuracy of gadolinium-enhanced magnetic resonance angiography of the pulmonary arteries in combination with magnetic resonance venography of the lower extremities for the detection of acute venous thromboembolic disease.

Obligations

Funding History:
   Fiscal Year 2006—$4,341,911
   Fiscal Year 2005—$2,301,770
Total Funding to Date—$6,643,681

Current Active Organizations and Grant Numbers

  1. Massachusetts General Hospital
    Boston, Massachusetts —HL-077149
  2. University of Michigan
    Ann Arbor, Michigan —HL-077150
  3. University of Calgary
    Calgary, Alberta —HL-077151
  4. Emory University
    Atlanta, Georgia —HL-077153
  5. Washington University
    St. Louis, Missouri —HL-077154
  6. George Washington University
    Washington, DC —HL-077155
  7. St. Joseph Mercy-Oakland
    Pontiac, Michigan —HL-077358
  8. New York University
    New York, New York —HL-081593
  9. St. Joseph Mercy-Oakland
    Pontiac, Michigan —HL-081594

Study of Acid Reflux Therapy for Children With Asthma, Initiated in Fiscal Year 2006

The purpose of this randomized controlled clinical trial is to investigate whether an approved proton-pump inhibitor lansoprazole will reduce asthma exacerbations in children with poorly controlled asthma, ages 6–16 years.

Obligations

Funding History:
   Fiscal Year 2006—$774,454
Total Funding to Date—$774,454

Current Active Organizations and Grant Numbers

  1. Emory University
    Atlanta, Georgia —HL-080433
  2. Johns Hopkins University
    Baltimore, Maryland —HL-080450

Blood Diseases and Resources

Blood and Marrow Transplant Clinical Research Network, Initiated in Fiscal Year 2001

See Chapter 11. Clinical Trials.

Center for Human Cell Therapy, Initiated in Fiscal Year 2004

The purpose of this Center is to serve as a unique resource to facilitate the development of new cellular therapies for a wide range of human diseases, especially heart, lung, and blood diseases and sleep disorders.

Obligations

Funding History:
   Fiscal Year 2006—$2,101,631
   Fiscal Year 2004–2005—$5,179,743
Total Funding to Date—$7,281,374

Current Active Organization and Grant Number

  1. CBR Institute for Biomedical Research
    Boston, Massachusetts —HL-074355

Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS), Initiated in Fiscal Year 2003

The purpose of this trial is to test whether a more aggressive transfusion strategy that maintains postoperative Hgb levels above 10 g/dl improves functional outcome in cardiovascular patients who are over age 50 and undergoing surgical hip fracture surgery compared to a more conservative strategy that withholds blood transfusion until the patient develops symptoms of anemia.

Obligations

Funding History:
   Fiscal Year 2006—$2,446,287
   Fiscal Years 2003–2005—$6,357,932
Total Funding to Date—$8,804,219

Current Active Organizations and Grant Numbers

  1. Robert Wood Johnson Medical School
    University of Medicine and Dentistry of New Jersey
    Piscataway, New Jersey —HL-073958
  2. Maryland Medical Research Institute, Inc.
    Baltimore, Maryland —HL-074815

Sickle Cell Disease Clinical Research Network, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Stroke With Transfusions Changing to Hydroxyurea (SWITCH), Initiated in Fiscal Year 2005

The purpose of this Phase III clinical trial is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with sickle cell anemia. Additional objectives include comparisons of growth and development, frequency of nonstroke neurological and other sickle-related events, and quality of life. The patient population will be black.

Obligations

Funding History:
   Fiscal Year 2006—$3,931,995
   Fiscal Year 2005—$3,345,345
Total Funding to Date—$7,277,340

Current Active Organizations and Grant Numbers

  1. St. Jude Children's Research Hospital
    Memphis, Tennessee —HL-077878
  2. Rho Federal Systems Division, Inc.
    Chapel Hill, North Carolina —HL-078987

Thalassemia (Cooley's Anemia) Clinical Research Network

See Chapter 11. Clinical Trials.

Transfusion Medicine/Hemostasis Clinical Research Network, Initiated in Fiscal Year 2002

See Chapter 11. Clinical Trials.

National Center on Sleep Disorders Research

Apnea Positive Pressure Long-Term Efficacy Study (APPLES), Initiated in Fiscal Year 2002

The purpose of this study is to evaluate the effectiveness of continuous positive airway pressure (CPAP) therapy to provide significant, stable, and long-term neurocognitive or other benefits to patients with obstructive sleep apnea (OSA). Investigators will identify specific neurocognitive deficits associated with OSA and determine which ones are reversible and most sensitive to the effects of CPAP therapy.

Obligations

Funding History:
   Fiscal Year 2006—$0
   Fiscal Years 2002–2005—$12,542,181
Total Funding to Date—$12,542,181

Current Active Organization and Grant Number

  1. Stanford University
    Stanford, California —HL-068060

Randomized Controlled Study of Adenotonsillectomy for Childhood Sleep Apnea, Initiated in Fiscal Year 2006

The purpose of this randomized controlled study is to compare adenotonsillectomy versus no surgery for obstructive sleep apnea in children.

Obligations

Funding History:
   Fiscal Year 2006—$2,267,140
Total Funding to Date—$2,267,140

Current Active Organizations and Grant Numbers

  1. Case Western Reserve University
    Cleveland, Ohio —HL-083075
  2. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-083129

Sleep Heart Health Study, Initiated in Fiscal Year 1999

The purpose of this multicenter observational study is to determine the degree to which sleep apnea is an independent or contributing risk factor for the development of cardiovascular or cerebrovascular disease.

Obligations

Funding History:
   Fiscal Year 2006—$907,548
   Fiscal Years 1999–2005—$19,603,693
Total Funding to Date—$20,511,241

Current Active Organizations and Grant Numbers

  1. University of California, Davis
    Davis, California —HL-053916
  2. New York University Medical Center
    New York, New York —HL-053931
  3. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HL-053934
  4. Johns Hopkins University
    Baltimore, Maryland —HL-053937
  5. University of Arizona
    Tucson, Arizona —HL-053938
  6. Boston University
    Boston, Massachusetts —HL-053941
  7. Missouri Breaks Research, Inc.
    Timberlake, South Dakota —HL-063429
  8. Case Western Reserve University
    Cleveland, Ohio —HL-063463
  9. Johns Hopkins University
    Baltimore, Maryland —HL-064360
  10. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-077813

NHLBI Research Centers (P50, U54, P30) Programs

Specialized Centers of Research (P50), Specialized Centers of Clinically Oriented Research (P50), and Centers of Excellence in Translational Human Stem Cell Research (P50) Programs

The NHLBI initiated the SCOR program in 1971 to encourage translational research—converting basic science findings to the clinic—in high priority areas. The SCOR concept emphasizes multidisciplinary research (i.e., basic science and clinical investigations) on diseases relevant to the Institute's mission. In 2002, the NHLBI revised the SCOR program—primarily on recommendation from the NHLBAC—to place more emphasis on clinical research projects. The newly developed SCCOR program still requires clinical and basic scientists to work together on a unified theme, but now requires at least 50 percent of the projects to be clinical. The Centers of Excellence in Translational Human Stem Cell Research was initiated in 2005 to accelerate the translation of basic scientific discoveries in human stem cell biology to new treatments for patients. Listed below is the funding history for the individual SCORs/SCCORs and Centers of Excellence supported by the Institute.

  Obligations (Dollars in Thousands)
Area of Concentration Period of Operation Prior to
FY 2006
FY 2006 Total to Date
Heart and Vascular Diseases Program        
Cardiac Dysfunction and Disease (SCCOR)
2005– $ 16,497 $ 16,923 $ 33,420
Molecular Medicine and Atherosclerosis
1997– 68,486 8,256 76,742
Pediatric Heart Developmnt and Disease (SCCOR)
2004– 26,528 12,891 39,419
Vascular Injury, Repair, and Remodeling (SCCOR)
2006– 15,324 15,324
Subtotal, Heart and Vascular Diseases Program   111,511 53,394 164,905
Lung Diseases Program        
Airway Biology and Pathogenesis of Cystic Fibrosis
1988– 62,373 3,631 66,004
Cellular and Molecular Mechanisms of Asthma
1996– 118,388 3,678 122,066
Host Factors in Chronic Lung Diseases (SCCOR)
2006– 7,939 7,939
Pathobiology of Fibrotic Lung Disease
1997– 44,451 1,894 46,345
Pathobiology of Lung Development
1996– 70,257 1,319 71,576
Translational Research in Acute Lung Injury (SCCOR)
2003– 35,632 12,329 47,961
Subtotal, Lung Diseases Program   331,101 30,790 361,891
Blood Diseases and Resources Program        
Hemostatic and Thrombotic Diseases (SCCOR)
2006– 8,063 8,063
Transfusion Biology and Medicine (SCCOR)
2005– 4,400 4,459 8,859
Subtotal, Blood Diseases and Resources Program   4,400 12,522 16,922
National Center on Sleep Disorders Research        
Neurobiology of Sleep and Sleep Apnea
1998– 41,310 6,215 47,525
Subtotal, National Center on Sleep Disorders Research   41,310 6,215 47,525
Total, Specialized Centers of Research (P50)   488,322 102,921 591,243
Centers of Excellence in Translational Human Stem Cell Research 2005– 1,509 1,453 2,962
Subtotal, Centers of Excellence in Translational Human Stem Cell Research   1,509 1,453 2,962
Total, (P50)   $489,831 $104,374 $594,205

Heart and Vascular Diseases Program

Cardiac Dysfunction and Disease

The purpose of this SCCOR is to foster multidisciplinary research on clinically relevant questions related to dysfunction and disease of the myocardium. The program will enable rapid application of basic science findings to the prevention, diagnosis, and treatment of cardiac disorders, including ischemic and other cardiomyopathies, left ventricular dysfunction, metabolic abnormalities, heart failure, and rhythm disturbances. Because some segments of the population disproportionately suffer from heart disease, research that addresses issues of health disparity will be emphasized.

Obligations

   Fiscal Year 2006—$16,922,848

Current Active Organizations and Grant Numbers

  1. Columbia University
    Health Science Center
    New York, New York —HL-077096
  2. University of Alabama at Birmingham
    Birmingham, Alabama —HL-077100
  3. University of Cincinnati
    Cincinnati, Ohio —HL-077101
  4. Cleveland Clinical Lerner College
    Cleveland, Ohio —HL-077107
  5. Washington University
    St. Louis, Missouri —HL-077113

Molecular Medicine and Atherosclerosis

The goal of this SCOR is to advance understanding of the etiology and pathobiology of the atherosclerotic lesion at the molecular level through modern methods and approaches of molecular medicine. Some of the subprojects have a large minority patient population.

Obligations

   Fiscal Year 2006—$8,256,190

Current Active Organizations and Grant Numbers

  1. Columbia University
    New York, New York —HL-056984
  2. Brigham and Women's Hospital
    Boston, Massachusetts —HL-056985
  3. University of California, San Diego
    La Jolla, California —HL-056989
  4. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-070128

Pediatric Heart Development and Disease

The purpose of this SCCOR is to foster multidisciplinary collaborations so that basic research advances can be translated rapidly to clinical care for children with heart disease. Research focus ranges from the genetic basis of heart valve disease to clinical trials of novel surgical strategies for congenital heart disease repair and immune modulation in pediatric heart transplantation. Two of the centers will have Clinical Research Skills Development Cores to train fellows and junior faculty in clinical research methods.

Obligations

   Fiscal Year 2006—$12,890,955

Current Active Organizations and Grant Numbers

  1. Children's Hospital Medical Center
    Cincinnati, Ohio —HL-074728
  2. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania —HL-074731
  3. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-074732
  4. Children's Hospital
    Boston, Massachusetts —HL-074734

Vascular Injury, Repair, and Remodeling

The purpose of this SCCOR is to foster multidisciplinary, clinically relevant research on vascular injury, repair, and remodeling. The program emphasizes development and translation of basic discoveries to understand the mechanisms of vascular disease; improved detection, characterization, staging, and management of vascular disease through use of cutting-edge methodologies, such as nanotechnology, molecular imaging, genomics, proteomics, and quantitative systems analysis; and development of new methods to treat vascular diseases such as cell- and gene-based therapies for regenerative medicine.

Obligations

   Fiscal Year 2006—$15,324,352

Current Active Organizations and Grant Numbers

  1. Washington University
    St. Louis, Missouri —HL-083762
  2. University of Texas Health
    Science Center
    Houston, Texas —HL-083794
  3. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-083799
  4. Stanford University
    Stanford, California —HL-083800
  5. Boston University Medical Campus
    Boston, Massachusetts —HL-083801
  6. Beth Israel Deaconess Medical Center
    Boston, Massachusetts —HL-083813

Lung Diseases Program

Airway Biology and Pathogenesis of Cystic Fibrosis

The goals of this SCOR are to investigate the basic mechanisms underlying cystic fibrosis, develop new hypotheses, and apply innovative strategies for approaching clinical and fundamental issues.

Obligations

   Fiscal Year 2006—$3,630,996

Current Active Organizations and Grant Numbers

  1. University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina —HL-060280
  2. University of Iowa
    Iowa City, Iowa —HL-061234

Cellular and Molecular Mechanisms of Asthma

The objective of this SCOR is to apply critical science and technology to increase understanding of cellular and molecular mechanisms of asthma, including those mechanisms underlying the biological impact of environmental factors.

Obligations

   Fiscal Year 2006—$3,678,237

Current Active Organizations and Grant Numbers

  1. University of New Mexico
    Albuquerque, New Mexico —HL-056384
  2. University of Wisconsin
    Madison, Wisconsin —HL-056396

Host Factors in Chronic Lung Diseases

The purpose of this SCCOR is to identify alterations in host responses and lung homeostasis and to determine how the dysregulation contributes to development or progression of chronic lung diseases. Enhanced understanding of these processes should facilitate identification of new targets for intervention, providing the basis for development of new therapeutic options for prevention and treatment of chronic lung diseases.

Obligations

   Fiscal Year 2006—$7,939,046

Current Active Organizations and Grant Numbers

  1. Duke University
    Durham, North Carolina —HL-084917
  2. Children's Hospital
    Pittsburgh, Pennsylvania —HL-084932
  3. University of North Carolina
    Chapel Hill, North Carolina —HL-084934

Pathobiology of Fibrotic Lung Disease

The purpose of this SCOR is to study cellular and molecular mechanisms involved in transition from inflammatory events associated with early fibrotic disease to later processes involving wound healing, repair, and fibrosis.

Obligations

   Fiscal Year 2006—$1,893,619

Current Active Organization and Grant Number

  1. University of Michigan at Ann Arbor
    Ann Arbor, Michigan —HL-056402

Pathobiology of Lung Development

The objective of this SCOR is to foster multidisciplinary research enabling basic science findings to be rapidly applied to clinical problems related to lung development. The program focuses on identification of the molecular variables involved in lung development and assessment of the impact of injury during critical periods.

Obligations

   Fiscal Year 2006—$1,319,019

Current Active Organization and Grant Number

  1. University of Colorado
    Health Sciences Center
    Denver, Colorado —HL-057144

Translational Research in Acute Lung Injury

The purpose of this SCCOR is to foster multidisciplinary research to improve the prevention, diagnosis, and treatment of acute lung injury and its more severe form—adult respiratory distress syndrome. This program includes Phase II clinical trials and studies of molecular mechanisms of inflammation and coagulation, gene and protein expression, and cell and animal models of lung injury.

Obligations

   Fiscal Year 2006—$12,329,192

Current Active Organizations and Grant Numbers

  1. Johns Hopkins University
    Baltimore, Maryland —HL-073994
  2. University of Washington
    Seattle, Washington —HL-073996
  3. University of California, San Francisco
    San Francisco, California —HL-074005
  4. University of Michigan at Ann Arbor
    Ann Arbor, Michigan —HL-074024

Blood Diseases and Resources Program

Hemostatic and Thrombotic Disorders

The purpose of this SCCOR is to conduct multidisciplinary research to improve the prevention, diagnosis, and treatment of thrombotic and bleeding disorders. The program will support rapid translation of basic science findings into clinical application.

Obligations

   Fiscal Year 2006—$8,062,898

Current Active Organizations and Grant Numbers

  1. Vanderbilt University
    Nashville, Tennessee —HL-081009
  2. Cleveland Clinic Lerner College
    Cleveland, Ohio —HL-081011
  3. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-081012

Transfusion Biology and Medicine

The purpose of this SCOR is to foster new approaches for improving the availability, efficacy, safety, and quality of blood and blood products for therapeutic uses. One of the centers has a large minority population.

Obligations

   Fiscal Year 2006—$4,459,397

Current Active Organizations and Grant Numbers

  1. Puget Sound Blood Center
    Seattle, Washington —HL-081015
  2. University of California, San Francisco
    San Francisco, California —HL-081027

National Center on Sleep Disorders Research

Neurobiology of Sleep and Sleep Apnea

The objective of this SCOR is to integrate molecular, cellular, and genetic approaches to sleep control with clinical investigations on the etiology and pathogenesis of sleep disorders, particularly sleep apnea.

Obligations

   Fiscal Year 2006—$6,214,930

Current Active Organizations and Grant Numbers

  1. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-060287
  2. Brigham and Women's Hospital
    Boston, Massachusetts —HL-060292
  3. University of California, Los Angeles
    Los Angeles, California —HL-060296

Centers of Excellence in Translational Human Stem Cell Research (P50) Program

The purpose of this program is to stimulate multidisciplinary collaboration among basic stem cell biologists, researchers, and clinicians with disease-specific expertise; physicians and surgeons skilled in innovative modes of cell delivery; and investigators experienced in developing and assessing animal models of human diseases to conduct projects such as preclinical studies for cell-based therapy employing human stem cells in animal models. Research findings will ultimately lead to innovative approaches for the prevention, treatment, and cure of disease, and will accelerate the translation of basic scientific discoveries into new therapies.

Obligations

   Fiscal Year 2006—$1,452,936

Current Active Organization and Grant Number

  1. University of California, Davis
    Davis, California —HL-085036

Comprehensive Sickle Cell Centers (U54) Program

The Comprehensive Sickle Cell Centers (CSCC) were instituted in FY 1972 to bridge the gap between research and service by combining basic and clinical research, clinical trials and applications training, and community service projects into one program. The patients recruited for the clinical studies are primarily from minority populations.

Obligations

   Fiscal Year 2006—$23,927,946

Current Active Organizations and Grant Numbers

  1. Children's Hospital and Research Center
    Oakland, California —HL-070583
  2. Thomas Jefferson University
    Philadelphia, Pennsylvania —HL-070585
  3. Rho Federal Systems Division, Inc.
    Chapel Hill, North Carolina —HL-070587
  4. University of Texas
    Southwestern Medical Center
    Dallas, Texas —HL-070588
  5. St. Jude Children's Research Hospital
    Memphis, Tennessee —HL-070590
  6. University of Southern California
    Los Angeles, California —HL-070595
  7. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania —HL-070596
  8. Duke University
    Durham, North Carolina —HL-070769
  9. Boston Medical Center
    Boston, Massachusetts —HL-070819
  10. Children's Hospital Research Center
    Cincinnati, Ohio —HL-070871
  11. Yeshiva University
    New York, New York —HL-070994

Specialized Centers for Cell-Based Therapies for Heart, Lung, and Blood Diseases (U54) Program

The Specialized Centers for Cell-Based Therapies Program, which includes a Data and Coordinating Center, was initiated in FY 2005 to support preclinical and clinical studies for cell-based therapy for heart, lung, and blood diseases and sleep disorders. A key feature of the program is the ability to conduct preclinical studies in the first year or two of the program, in order to meet the requirements for an Investigational New Drug application prior to initiating clinical studies. Clinical studies are expected to be initiated by the beginning of the third year.

Obligations

   Fiscal Year 2006—$6,901,976

Current Active Organizations and Grant Numbers

  1. Baylor College of Medicine
    Houston, Texas —HL-081007
  2. EMMES Corporation
    Rockville, Maryland —HL-081021
  3. Johns Hopkins University
    Baltimore, Maryland —HL-081028
  4. Massachusetts General Hospital
    Boston, Massachusetts —HL-081030

Centers for AIDS Research (P30) Program

The NHLBI, along with five other NIH Institutes, contributes to the support of six Centers for AIDS Research that were established to provide a multidisciplinary environment that promotes basic, clinical, behavioral, and translational research activities in the prevention, detection, and treatment of HIV infection and AIDS. Almost half of the patient population comes from minority groups.

Obligations

   Fiscal Year 2006—$2,960,699

Current Active Organizations and Grant Numbers

  1. New York University
    School of Medicine
    New York, New York —AI-027742
  2. University of Washington
    Seattle, Washington —AI-027757
  3. University of California, San Francisco
    San Francisco, California —AI-027763
  4. University of Alabama at Birmingham
    Birmingham, Alabama —AI-027767
  5. University of California, Los Angeles
    Los Angeles, California —AI-028697
  6. Baylor University
    Houston, Texas —AI-036211
  7. University of California, San Diego
    La Jolla, California —AI-036214
  8. Case Western Reserve University
    Cleveland, Ohio —AI-036219
  9. University of Massachusetts
    Medical School
    Worcester, Massachusetts —AI-042845
  10. Miriam Hospital
    Providence, Rhode Island —AI-042853
  11. University of Pennsylvania
    Philadelphia, Pennsylvania —AI-045008
  12. Emory University
    Atlanta, Georgia —AI-050409
  13. University of North Carolina
    at Chapel Hill
    Chapel Hill, North Carolina —AI-050410
  14. Yeshiva University
    New York, New York —AI-051519
  15. University of Colorado
    Health Sciences Center
    Denver, Colorado —AI-054907
  16. Vanderbilt University
    Nashville, Tennessee —AI-054999
  17. Harvard Medical School
    Boston, Massachusetts —AI-060354
  18. Duke University
    Durham, North Carolina —AI-064518

Back to Top

« Back

Next »

Fact Book Table of Contents

Skip footer links and go to content